A randomized prospective crossover trial of amlodipine in pediatric hypertension

J W Rogan1, D A Lyszkiewicz, D Blowey

  • 1The Department of Pediatrics and Research Institute, The Hospital for Sick Children, Toronto, Canada.

Insights

Amlodipine is as effective as other calcium channel blockers for treating hypertension in children. Its liquid form and once-daily dosing may improve medication adherence in pediatric patients.

Area of Science:

  • Pediatric Nephrology
  • Cardiovascular Pharmacology
  • Clinical Hypertension

Background:

  • Pediatric hypertension requires effective and manageable treatment options.
  • Amlodipine offers potential advantages for pediatric use, including liquid formulation and once-daily dosing.
  • Standard long-acting calcium channel blockers like felodipine and nifedipine are commonly used.

Purpose of the Study:

  • To compare the efficacy and patient compliance of amlodipine versus standard long-acting calcium channel blockers (felodipine or nifedipine) in hypertensive children.
  • To evaluate blood pressure control and adherence in pediatric patients receiving amlodipine or other calcium channel blockers.

Main Methods:

  • A randomized, prospective, crossover study involving 11 hypertensive children (aged 9-17 years).
  • Electronic monitoring was used to assess patient compliance during 30-day treatment periods for each drug.
  • 24-hour ambulatory blood pressure monitoring assessed systolic (SBP) and diastolic (DBP) blood pressures during day and night.

Main Results:

  • No significant differences in mean systolic and diastolic blood pressure were observed between amlodipine and nifedipine/felodipine.
  • 24-hour blood pressure monitoring showed no significant differences in daytime or nighttime SBP and DBP between treatments.
  • Patient compliance rates were similar for amlodipine and the other calcium channel blockers.

Conclusions:

  • Amlodipine demonstrates comparable efficacy to nifedipine and felodipine in managing hypertension in pediatric nephrology patients.
  • Amlodipine's liquid formulation and once-daily administration make it a potentially optimal choice for treating young children.
  • The study supports amlodipine as an effective and well-tolerated option for pediatric hypertension management.

Related Concept Videos

Crossover Experiments01:16

Crossover Experiments

Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...